medigraphic.com
ISSN 0016-3813 (Impreso)

2017, Número 1

<< Anterior Siguiente >>

Gac Med Mex 2017; 153 (1)


Asociación de las variantes V249I y T280M del receptor de fractalcina CX3CR1 con el grosor de la íntima-media de la carótida (cIMT) en población mexicana con diabetes tipo 2 (DT2)

Gómez-Díaz RA, Gutiérrez J, Contreras-Rodriguez A, Valladares-Salgado A, Tanus-Hajj J, Mondragón-González R, Talavera JO, Mejía-Benitez MA, García-Mena J, Cruz M, Wacher NH

Idioma: Ingles.
Referencias bibliográficas: 44
Paginas: 49-56
Archivo PDF: 106.96 Kb.


RESUMEN

Objetivo: Evaluar la asociación de las variantes V249I y T280M del receptor CX3CR1 de fractalcina con el cIMT en sujetos mexicanos con y sin DT2. Métodos: Se analizaron las variantes V249I y T280M del receptor CX3CR1 de fractalcina con sondas TaqMan en 111 pacientes con DT2 y 109 controles sanos. Se determinaron las concentraciones de glucosa, el perfil de lípidos y el porcentaje de hemoglobina glucosilada A1c (HbA1c). Resultados: Se observó un incremento significativo del cIMT en los pacientes con DT2 (0.979 ± 0.361 mm) versus controles sanos (0.588 ± 0.175 mm). En los sujetos portadores de la variante MM del polimorfismo T280M la HbA1c fue mayor (p = 0.008). Los factores de riesgo clásicos para aterosclerosis no mostraron diferencias entre los portadores de T280M y los de V249I. En los controles sanos el cIMT se asoció con la variante II249 (0.747 ± 0.192 mm; p = 0.041) y, al ajustar factores como la edad, el género y el índice de masa corporal, la diferencia permaneció estadísticamente significativa (7.7; intervalo de confianza al 95%: 1.269-47.31; p = 0.027). Conclusiones: El genotipo VI249 del receptor de fractalcina mostró un rol protector en pacientes con DT2. El genotipo MM280 se asoció con mayor cIMT en mexicanos con o sin DT2.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Van der Heijden AA, van’t Riet E, Bot SD, et al. Risk of recurrent cardiovascular event in individuals with type 2 diabetes of intermediate hyperglycemia: The Hoorn Study. Diabetes Care. 2013;36:3498-502.

  2. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33:442-9.

  3. Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med. 2007;262:408-14.

  4. Okayama KI, Mita T, Gosho M, et al. Carotid intima-media thickness progression predicts cardiovascular events in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;101:286-92.

  5. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21:93-111.

  6. Napoli N, Zardi E, Strollo R, et al. Increased carotid thickness in subjects with recently-diagnosed diabetes from rural Cameroon. PLoS One. 2012;7:e41316.

  7. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3Cl1). Circulation. 2003;108:2498-504.

  8. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-4.

  9. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521-30.

  10. Flierl U, Schäfer A. Fractalkine--a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost. 2012;108:457-63.

  11. Matsumiya T, Ota K, Imaizumi T, Yoshida H, Kimura H, Satoh K. Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF- alpha in post-transcriptional regulation of CX3CL1. J Immunol. 2010;184:4205-14.

  12. Gan AM, Butoi ED, Manea A, et al. Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways. Cell Tissue Res. 2013;351:161-74.

  13. Ramos MV, Fernández GC, Brando RJ, et al. Interleukin-10 and interferon- gamma modulate surface expression of fractalkine-receptor (CX(3) CR1) via PI3K in monocytes. Immunology. 2010;129:600-9.

  14. Franco L, Williams FM, Trofimov S, Surdulescu G, Spector T, Livshits G. Elevated plasma fractalkine levels are associated with higher levels of IL-6, Apo-B, LDL-C and insulin, but not with body composition in a large female twin sample. Metabolism. 2013;62:1081-7.

  15. Shah R, Hinkle CC, Ferguson JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011;60:1512-8.

  16. Stolla M, Pelisek J, von Brühl MLet al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One. 2012;7:e43572.

  17. Richter B, Koller L, Hohensinner PJ, et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost. 2012;108:1220-7.

  18. Njerve IU, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I. Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus. Metab Syndr Relat Disord. 2012;10:400-6.

  19. Postea O, Vasina EM, Cauwenberghs S, et al. Contribution of platelet CX(3) CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. Arterioscler Thromb Vasc Biol. 2012;32:1186-93.

  20. Fumagalli S, Perego C, Ortolano F, De Simoni MG. CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia. 2013;61:827-42.

  21. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 1994;12:593-633.

  22. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL. Effects of fractalkine receptor variants on common carotid artery intimamedia thickness. Stroke. 2006;37:1558-61.

  23. Niessner A, Marculescu R, Haschemi A, et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation. Thromb Haemost. 2005;93:949-54.

  24. Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring). 2011;19:222-7.

  25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):S67-74.

  26. Mejía-Benítez A, Klünder-Klünder M, Yengo L, et al. Analysis of the contribution of FTO, NPC1, ENPP1, NEGR1, GNPDA2 and MC4R genes to obesity in Mexican children. BMC Med Genet. 2013;14:21.

  27. Wallace GR, Vaughan RW, Kondeatis E, et al. A CX3CR1 genotype associated with retinal vasculitis in patients in the United Kingdom. Invest Ophthalmol Vis Sci. 2006;47:2966-70.

  28. Ghilardi G, Biondi ML, Turri O, Guagnellini E, Scorza R. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke. 2004;35:1276-9.

  29. Li C, Lu SC, Hsieh PS, et al. Distribution of human chemokine (C-X3-C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. Int J Immunogenet. 2005;32:99-106.

  30. Lee KY, Sohn YH, Baik JS, Kim GW, Kim JS. Arterial pulsatility as an index of cerebral microangiopathy in diabetes. Stroke. 2000;31:1111-5.

  31. Su TC, Chien KL, Jeng JS, et al. Age- and gender-associated determinants of carotid intima-media thickness: a community-based study. J Atheroscler Thromb. 2012;19:872-80.

  32. Shah AS, Dolan LM, Kimball TR, et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:3740-5.

  33. Liu YP, Zhan WW, Zhang YF, et al. Carotid intima-media thickness and stiffness in relation to type 2 diabetes in Chinese. Endocrine. 2007;31: 289-93.

  34. O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J. 2010;31:1682-9.

  35. Moore XL, Michell D, Lee S, et al. Increased carotid intima-media thickness and reduced distensibility in human class III obesity: independent and differential influences of adiposity and blood pressure on the vasculature. PLoS One. 2013;8:e53972.

  36. George JM, Bhat R, Pai KM, S A, Jeganathan J. The carotid intima media thickness: a predictor of the clinical coronary events. J Clin Diagn Res. 2013;7:1082-5.

  37. Debette S, Bevan S, Dartigues JF, et al. Fractalkine receptor/ligand genetic variants and carotid intima-media thickness. Stroke. 2009;40:2212-4.

  38. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925-8.

  39. Kimouli M, Miyakis S, Georgakopoulos P, Neofytou E, Achimastos AD, Spandidos DA. Polymorphisms of fractalkine receptor CX3CR1 gene in patients with symptomatic and asymptomatic carotid artery stenosis. J Atheroscler Thromb. 2009;16:604-10.

  40. Cefalu WT. Fractalkine: a cellular link between adipose tissue inflammation and vascular pathologies. Diabetes. 2011;60:1380-2.

  41. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001;89:401-7.

  42. McDermott DH, Fong AM, Yang Q, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111; 1241-50.

  43. Niessner A, Marculescu R, Haschemi A, et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation. Thromb Haemost. 2005;93:949-54.

  44. Lavergne E, Labreuche J, Daoudi M, et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:847-53.




2020     |     www.medigraphic.com